Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination

✍ Scribed by Chen Li; Min Yan; Jun Chen; Min Xiang; Zheng Gang Zhu; Hao Ran Yin; Yan Zheng Lin

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 123 KB
• Volume: 102
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.21628

✦ Synopsis

Abstract

Background

The prognosis for gastric cancer patients with peritoneal dissemination is very poor. The purpose of this study was to evaluate the survival benefit from gastrectomy with hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer patients with peritoneal dissemination.

Methods

From 1992 to 2002, 128 gastric cancer patients with peritoneal dissemination underwent surgery at the Department of Surgery, Ruijin Hospital, Shanghai, China. The clinicopathological characteristics and survival were compared between the resection and the non‐resection groups, and between the resection alone and the resection with HIPEC groups.

Results

The 5‐year survival rates were 5.5% for patients in the resection group and 0% for patients in the non‐resection group (P < 0.001). Multivariate analysis showed surgical resection was significantly associated with better prognosis in gastric cancer patients with peritoneal dissemination. In the patients who underwent resection, the survival difference between the resection alone and the resection with HIPEC groups was significant (P = 0.025), and HIPEC was an independent prognostic factor by multivariate analysis.

Conclusions

The HIPEC procedure was an independent prognostic factor after resection for patients with peritoneal dissemination. Therefore, gastrectomy with HIPEC may be an option for those patients. The survival benefit of this strategy should be validated by large cohort prospective clinical trials. J. Surg. Oncol. 2010;102:361–365. © 2010 Wiley‐Liss, Inc.